The 5-hydroxymethylcytosine landscape of prostate cancer
M Sjöström, SG Zhao, S Levy, M Zhang, Y Ning… - Cancer research, 2022 - AACR
Abstract Analysis of DNA methylation is a valuable tool to understand disease progression
and is increasingly being used to create diagnostic and prognostic clinical biomarkers …
and is increasingly being used to create diagnostic and prognostic clinical biomarkers …
Methylome-wide sequencing detects DNA hypermethylation distinguishing indolent from aggressive prostate cancer
A critical need in understanding the biology of prostate cancer is characterizing the
molecular differences between indolent and aggressive cases. Because DNA methylation …
molecular differences between indolent and aggressive cases. Because DNA methylation …
Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways
S Bhattacharyya, K Pradhan, N Campbell… - Genome …, 2017 - genome.cshlp.org
Transcriptional deregulation of oncogenic pathways is a hallmark of cancer and can be due
to epigenetic alterations. 5-Hydroxymethylcytosine (5-hmC) is an epigenetic modification …
to epigenetic alterations. 5-Hydroxymethylcytosine (5-hmC) is an epigenetic modification …
Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in …
TM Storebjerg, SH Strand, S Høyer, AS Lynnerup… - Clinical …, 2018 - Springer
Background Prognostic tools for prostate cancer (PC) are inadequate and new molecular
biomarkers may improve risk stratification. The epigenetic mark 5-hydroxymethylcytosine …
biomarkers may improve risk stratification. The epigenetic mark 5-hydroxymethylcytosine …
The application of genome-wide 5-hydroxymethylcytosine studies in cancer research
JP Thomson, RR Meehan - Epigenomics, 2017 - Taylor & Francis
Early detection and characterization of molecular events associated with tumorgenesis
remain high priorities. Genome-wide epigenetic assays are promising diagnostic tools, as …
remain high priorities. Genome-wide epigenetic assays are promising diagnostic tools, as …
High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer
SH Strand, S Hoyer, AS Lynnerup, C Haldrup… - Clinical …, 2015 - Springer
Background Prostate cancer (PC) can be stratified into distinct molecular subtypes based on
TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial …
TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial …
Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis
Background Despite the significant global loss of DNA hydroxymethylation marks in prostate
cancer tissues, the locus-specific role of hydroxymethylation in prostate tumorigenesis is …
cancer tissues, the locus-specific role of hydroxymethylation in prostate tumorigenesis is …
5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages
Hydroxymethylcytosine (5hmC) is an important mammalian DNA epigenetic modification
that has been linked to gene regulation and cancer pathogenesis. Here we explored the …
that has been linked to gene regulation and cancer pathogenesis. Here we explored the …
Transcriptome-wide 5-methylcytosine functional profiling of long non-coding RNA in hepatocellular carcinoma
Y He, Q Shi, Y Zhang, X Yuan, Z Yu - Cancer Management and …, 2020 - Taylor & Francis
Background Growing evidence indicates that methylation status is associated with the
pathogenesis of numerous types of cancers. Among these, hepatocellular carcinoma (HCC) …
pathogenesis of numerous types of cancers. Among these, hepatocellular carcinoma (HCC) …
[HTML][HTML] Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1
L Spans, T Van den Broeck, E Smeets, S Prekovic… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The clinical heterogeneity of prostate cancer (PCa) makes it difficult to identify those patients
that could benefit from more aggressive treatments. As a contribution to a better …
that could benefit from more aggressive treatments. As a contribution to a better …